TrialBritish journal of haematology2015

The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.

Beth A Christian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.